Unveiling Insights with
Panome Proteomics

Panome Bio’s discovery proteomics approach is compatible with many sample types including tissues, cells, biofluids, etc.

Panome Bio’s discovery proteomics approach is compatible with many sample types including tissues, cells, biofluids, etc. Our cell and tissue-based MS Proteomics approach leverages label-free bottom-up untargeted proteomics to identify a wide range of proteins in complex biological samples. This approach offers exceptional sensitivity and specificity, allowing for unbiased assessment of the proteome across species and sample types. Additionally, interrogation of peptide levels results provides insights into differences between proteoforms that may be undetectable from whole-protein analyses, improving biomarker discovery and gaining insights into various biological processes.

Advantages of our Tissue-Based Discovery Proteomics Platform:

• Compatible with many sample types including tissues, cells, biofluids, and more.
• Can simultaneously target multiple proteins, making it suitable for large-scale proteome profiling
• Minimal sample volume/weight required (25 µL, 10 mg)
• Can expect upwards of 3,000 proteins identified

Targeted proteomics assays are used in proteomics research to quantify and characterize specific sets of proteins within a complex biological sample.

Targeted LC/MS proteomics assays are used to quantify and characterize specific sets of proteins within a complex biological sample. This approach provides quantitative measurements on specific proteins with high precision and is often used to validate biomarker candidates, study signaling pathways, or monitor disease-related protein changes in a controlled and targeted manner as research programs move towards clinical development.

Panome Bio’s targeted proteomics approach uses paired unlabeled and stable-isotope labeled internal standards for every peptide and are all validated according to CPTAC guidelines, yielding the highest quality assays with superior specificity, reproducibility and accuracy.

Panome Bio’s targeted proteomics capabilities can be accessed through large, pre-validated panels or through custom development of assays targeting your proteins of interest. Our predefined quantitative protein panels consist of 270 proteins in human plasma or 375 proteins in mouse plasma and include proteins associated with cancer, cardiovascular disease, inflammation, and other diseases and signaling pathways.

Advantages of our Targeted Proteomics Platform:

• High multiplexing capabilities (100s of proteins per run) and low sample volumes (25-100 uL)
• Reproducible and tested for interferences
• No antibodies required – High purity paired heavy/light peptide standards are used for precise quantitation of every targeted protein
• Proven linear response over six orders of magnitude
• Absolute specificity due to the combination of peptide-specific retention time, fragmentation patterns, and m/z data.